-
Mashup Score: 0
Whether via the strain of academic advancement or hyper-competitive industry-funded drug-development landscape,1 there has been increasing focus to shift c
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017 - 5 hour(s) ago
AbstractBackground. Approximately 40,000 individuals die from metastatic breast cancer each year. We examined what fractions of annual breast cancer-specif
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach | JCO Oncology Practice - 7 day(s) ago
Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into the bloodstream. Clinical utility of ctDNA in breast cancer has been explored in both metastatic breast cancer (MBC) and early-stage breast cancer (EBC) settings. In MBC,…
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Inferring gender from first names: Comparing the accuracy of Genderize, Gender API, and the gender R package on authors of diverse nationality - 24 day(s) ago
Author summary Gender disparities in academia have prompted researchers to investigate gender gaps in professorship roles and publication authorship. Of particular concern are the gender gaps in cancer clinical trial authorship. Methodologies that evaluate gender disparities in academia often rely on tools that infer gender from first names. Tools that predict gender from first names are often used in methodologies that determine the gender ratios of academic departments or publishing authors in a discipline. However, researchers must choose between different gender predicting tools that vary in their accuracy, ease of use, and cost. We evaluated the binary gender prediction accuracy of Genderize, Gender API, and the gender R package on a gold-standard dataset of 32,968 clinical trialists from around the world. Genderize and Gender API are commercially available, while the gender R package is free and open source. We found that Genderize and Gender API were more accurate than the gende
Source: journals.plos.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Welcome! You are invited to join a webinar: HORMONE RECEPTOR POSITIVE BREAST CANCER. After registering, you will receive a confirmation email about joining the webinar.
Source: us02web.zoom.usCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19With new investments and affiliation agreements, Lifespan to become Brown University Health - 2 month(s) ago
Lifespan and Brown University finalized agreements to expand their longtime affiliation, outlining new financial investments, academic and governance terms, and a new name for Rhode Island’s largest health care system.
Source: www.brown.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26Home - Paddle for Progress RI - 2 month(s) ago
Paddle for Progress RI is a charity organization with the goal of raising awareness and funds for the the Lifespan Breast Cancer Multidisciplinary Clinic and Lifespan Breast Cancer Research at Rhode Island Hospital.
Source: paddleforprogressri.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Registration - SGBCC 2025 - 2 month(s) ago
Conference Registration The 19th St.Gallen International Breast Cancer Conference will take place in Vienna, Austria from 12 – 15 March 2025 and we are excited to welcome delegates from all over the world. Make sure to register early to take advantage of our reduced early bird fees! Please note
Source: www.sg-bcc.orgCategories: General Medicine News, Hem/OncsTweet-
Omission of axillary dissection in pts w/low volume nodal disease undergoing upfront surgery is supported by 🔝evidence, but role of axillary radiation is unclear So, @SG_BCC invited 4️⃣ internationally recognized experts to debate! 🗓️MARCH 2025 https://t.co/ZHw8vEIASJ #SGBCC2025 https://t.co/j6VidN7Kgv
-
-
Mashup Score: 45
PURPOSE As metastatic breast cancer (mBC) treatment evolves, there is a need to understand how clinical meaningfulness, or a meaningful change in a patient’s daily life, and clinically meaningful outcomes inform patient-centered care. Partnering with key stakeholders ensures patient-centered research incorporates the knowledge and expertise of advisors with lived experience. We describe a multistakeholder engagement approach to examine how people living with mBC (PLWmBC), caregivers, and health care providers interpret clinical meaningfulness and clinically meaningful outcomes and their influence on mBC treatment decision making and care. METHODS Qualitative focus groups with PLWmBC, caregivers, and health care providers were conducted and analyzed along three overarching themes: interpretations of clinical meaningfulness and clinically meaningful outcomes; treatment recommendations, preferences, and decisions; and implications for clinical practice. Patient-led and professional organi
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Mandatum | Journal of Clinical Oncology - 2 month(s) ago
In this poem, a patient refuses curative treatment. It explores ideas of consent, understanding, and the spirit.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
“Nailing down” risk and improving outcomes in early-stage breast cancer https://t.co/kjDTkyIQTz @coffeemommy @KalinskyKevin @OncoAlert https://t.co/UE6xJ16YVf